Stallergenes

Stallergenes S.a.

Philippe Moingeon

Emmanuel Nony

Laurent Mascarell

Thierry Batard

Julien Bouley

Véronique Bodo

Laurence Van Overtvelt

Alain Razafindratsita

Aline Zimmer

Sophie Tourdot

Bertrand Villet

Claire Gueguen

Noémie Caillot

Vincent Lombardi

Laetitia Bussieres

Sabi Airouche

Nathalie Saint-Lu

Hélène Moussu

Karine Jain

Véronique Bordas

Ingrid Bulder

The present invention concerns the use of IL-10 as a biological marker for predicting the responsiveness of a house dust mite allergic patient to house dust mite allergen immunotherapy.

IL-10 as a predictive biomarker of responsiveness to house dust mite allergen immunotherapy

The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.

Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids

The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.

Markers of immune response

The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.

Sialylated fetuin-A as a marker of immunotherapy efficacy

The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from aand a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance.

Compositions for antigen-specific induction of tolerance

The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.

Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy

The invention relates to proteins for use as markers for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.

Biomarkers of immunotherapy efficacy

The present invention concerns a method for producing a recombinant2 protein (rDer p 2), comprising the steps of cultivating ayeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from saidyeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.

Recombinant Der P 2 expressed in Pichia Pastoris as a 'natural-like' allergen for immunotherapy and diagnostic purposes

The present invention concerns the use of immunoglobulins of IgGtype, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.

Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa

The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.

Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance

[object Object]

The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.

Growing community of inventors

Verrieres le Buisson, France

Philippe Moingeon